Companies Gilead Sciences Inc FollowJuly 21 (Reuters) - Gilead Sciences Inc (GILD.O) said on Friday it was stopping a late-stage trial of its blood cancer combination treatment following an analysis that showed it would not be effective. Gilead, whose shares dropped over 1% in after-market trading, recommended that treatment with magrolimab in patients with MDS should be stopped. The company gained access to magrolimab with its $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is also in development for other types of cancer such as acute myeloid leukemia and solid tumours. Reporting by Sriparna Roy in Bengaluru Editing by Vinay DwivediOur Standards: The Thomson Reuters Trust Principles.

---

Persons: Gilead, Robert W, Baird, Brian Skorney, Magrolimab, Sriparna Roy, Vinay Dwivedi Organizations: Gilead Sciences, Gilead Sciences Inc, Seven Inc, Thomson Locations: Bengaluru